Skip to content
Disclosery

Royalty Pharma Sub-Manager, LLC

Follow

13F filer, CIK 2081668, New York, NY

Royalty Pharma Sub-Manager, LLC reported $171,312,250 across 4 holdings for the quarter ended 2025-12-31, in a 13F-HR/A filed 2026-08-21.

Filed (acceptance time not in the bulk data set), ingested 13F-HR/A 0002081668-26-000015

Period
2025-12-31
Reported value
$171M
Holdings
4
Top 10 weight
100%
New
Sold out

Part of the filer group Royalty Pharma Sub-Manager, LLC

How groups are built

Holdings, Q4 2025

Share positions as resolved from 13F-HR/A 0002081668-26-000015, largest first. % of portfolio is the value over $171,312,250, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 980,392 shares 980,392$62.3M36.36%Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,263,150 shares 1,263,150$45.9M26.77%Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 2,936,507 shares 2,936,507$33.2M19.35%Timeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 3,846,154 shares 3,846,154$30M17.51%Timeline

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0002081668-26-000003 superseded2026-04-01acceptance time not in the bulk data set
13F-HR/A 0002081668-26-000015 baserestatement2026-08-21acceptance time not in the bulk data set